The antibody clone 24C18.3 binds to SFRP5 which could be applied to treattype 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Figure 1 A timeline and plot for the in vivo study evaluating the pharmacokinetic properties of anti-SFRP5 monoclonal antibody subclones.
B6.V~Z.ep 00 I male mice (3 each for each time point) were injected i.p. with one of the anti-SFRP5 monoclonal antibody subclones. Blood was collected before injection (0) and 1, 3, 6, 24, 48, 72, 96 and 168 hours post injection. The plot shows the concentration of monoclonal antibody in the blood at each time point. Data for subclones 24P2.2 (epitope bin 1), 12E6.2 (epitope bin 2) and 24C18.3 (epitope bin 2) are shown.
Figure 2 A series of two plots showing the results of glucose tolerance tests performed at week 2 (Figure A) and week 4 (Figure B) after injection into 6 week old B6.
V-Lep 00 II male mice. Each plot shows glucose levels (mg/dL) over a 60 minute period after oral injection of glucose (Ig/kg) in mice treated with an IgG control antibody or subclone 24P2.2, 12E6.2, 24C 18.3, or 1702.1. Mice were treated with 30 mgs/kg of antibody, i.p, two-times per week over the course of the four week study. N=12 for each cohort. 2-way ANOVA statistical significance (asterisks) comparing mice treated with subclone 24C18.3 to IgG control mice is shown.
Figure 3 A series of four bar graphs showing the results of fasting blood glucose levels (A), fasting serum insulin levels (B) over time after injection into 6 week old B6. Y-Lep obIJ male mice.
Each bar graph shows results for mice treated with an igG control antibody or subclone 24P2.2, 12E6.2, 24C 18.3, or 1702.1. Mice were treated with 30 mgs/kg of antibody, i.p, two-times per week over the course of the four week study. N;=12 for each cohort. 2-way ANOVA statistical significance (asterisks) comparing mice treated with a subclone to IgG control mice.
Figure 4 A bar graph showing the results of fasting c-peptide levels 4 weeks after treatment.
Results are shown for mice treated with an IgG control antibody or subclone 24P2.2, 12E6.2, 24C18.3, or 1702.1. Mice were treated with 30 mgs/kg of antibody, i.p, two-times per week over the course of the four week study. N=12 for each cohort. 2-way ANOVA statistical significance (asterisks) comparing mice treated with a subclone to IgG control mice is shown.
Figure 5 The addition of anti-SF P5 (clone 24C18.3) to cells treated with both W~NT3a (180 ng/ml) and recombinant SFRP5 (6 ug/ml) rescues the stimulatory effect of WNT3a on 293/TCF cells in a dose-dependent manner.
Figure 6 Anti-SFRP5 monoclonal antibody clones, 24C18.3, 12E6.2 and 24P.2, were compared for their ability to inhibit SFRPS-mediated inhibition of WNT3a on 293/TCF cells.
Figure 7 A plot for the in vivo study evaluating the pharmacokinetic properties of anti-SFRP5 monoclonal antibody clones 24C18.3, 12E6.2 and 24P2.2.
B6.V-Iep ob/J male mice (3 each for each time point) were injected intraperitoneally with one of the anti-SFRP5 monoclonal antibody clones. Blood was collected before injection (0) and 1, 3, 6, 24, 48, 72, 96 and 168 hours post injection. The plot shows the concentration of monoclonal antibody in the blood at each time point. Concentrations were determined by Hi ISA using recombinant mouse SFRP5 to coat plates. Standard deviation is shown.
Figure 8 A series of plots and graphs showing the effects of anti-SFRP5 monoclonal antibody treatment in B6.Y-Lep male mice.
6 week old B6.V~Z.ep J male mice were injected with an IgG control antibody or one of the 3 anti-SFRP5 monoclonal antibody clones; 24C18.3, 12E6.1 or 24P2.2. Glucose tolerance tests were performed at week 1 (A), week 2 (B) and week 4 (C), Each plot shows glucose levels (mg/dL) over a 60 minute period after oral injection of glucose (1 g/kg for week L 2 g/kg for weeks 2 and 4). Plots for body weight over time (D) and fasting blood glucose levels (E) are shown. Bar graphs show the ratio of insulin to proinsulin (F) and C-peptide to proinsulin (G) present in the serum of 4 hour fasted mice upon harvest at week 5. Mice were treated with 30 mgs/kg of antibody, intraperitoneally, two-times per week over the course of the study. N=T2 for each cohort. 2-way ANOVA statistical significance (asterisks) comparing mice treated with anti-SFRP5 monoclonal antibody to IgG control mice. Standard error of the mean is shown.
Figure 9 A plot and 2 bar graphs showing the effect of anti-SFRP5 monoclonal antibody clone, 24C18.3, on C57BL/6J male mice, 20 week old C57BL/6J male mice fed a 60% high fat diet for at least 8 weeks were injected with an IgG control antibody (30 mgs/kg) or anti-SFRP5 monoclonal antibody clone, 24C 18.3 (30 mgs kg or 3 mgs/kg).
A glucose tolerance test was performed at week 2 on 4 hour fasted mice (A). The plot shows glucose levels (mg/dL) over a 60 minute period after oral injection of glucose (2 g/kg). The first bar graphs (B) shows the ratio of C-peptide to proinsulin in the serum of IgG-treated mice (30 mgs/kg) compared to 24C18.3-treated mice (30 mgs/kg). The second bar graphs (C) shows the ratio of C-peptide to proinsulin content in the pancreas of IgG-treated mice (30 mgs/kg) compared to 24C 18.3-treated mice (30 mgs/kg).
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-899 | Recombinant Anti-human SFRP5 Antibody | ELISA, WB, IF, FuncS | IgG |
MHH-899 | Recombinant Human Anti-human SFRP5 Antibody | WB, Neut, FuncS | IgG |
HPAB-0485-YJ | Human Anti-SFRP5 Recombinant Antibody (HPAB-0485-YJ) | ELISA, FuncS | Humanized IgG |
HPAB-0486-YJ | Human Anti-SFRP5 Recombinant Antibody (HPAB-0486-YJ) | ELISA, FuncS | Humanized IgG |
VS3-QX1006 | Mouse Anti-SFRP5 Recombinant Antibody (clone 4G04) | WB, IP, IF | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-899-F(E) | Recombinant Anti-human SFRP5 Antibody Fab Fragment | WB, ELISA, FuncS | Fab |
MHH-899-F(E) | Recombinant Human Anti-human SFRP5 Antibody Fab Fragment | WB, IF, FuncS | Fab |
HPAB-0008-DJB-F(E) | Mouse Anti-SFRP5 Recombinant Antibody (clone 24C18.3); Fab Fragment | ELISA, Block | Mouse Fab |
HPAB-0485-YJ-F(E) | Human Anti-SFRP5 Recombinant Antibody; Fab Fragment (HPAB-0485-YJ-F(E)) | ELISA | Humanized Fab |
HPAB-0486-YJ-F(E) | Human Anti-SFRP5 Recombinant Antibody; Fab Fragment (HPAB-0486-YJ-F(E)) | ELISA | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-899-S(P) | Recombinant Anti-human SFRP5 Antibody scFv Fragment | ELISA, WB, IP, FuncS | scFv |
MHH-899-S(P) | Recombinant Human Anti-human SFRP5 Antibody scFv Fragment | FC, RIA, Biosensors, FuncS | scFv |
HPAB-0008-DJB-S(P) | Mouse Anti-SFRP5 Recombinant Antibody (clone 24C18.3); scFv Fragment | ELISA, Block | Mouse scFv |
HPAB-0485-YJ-S(P) | Human Anti-SFRP5 Recombinant Antibody; scFv Fragment (HPAB-0485-YJ-S(P)) | ELISA | Humanized scFv |
HPAB-0486-YJ-S(P) | Human Anti-SFRP5 Recombinant Antibody; scFv Fragment (HPAB-0486-YJ-S(P)) | ELISA | Humanized scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-436CT | Mouse Anti-SFRP5 Recombinant Antibody (TAB-436CT) | WB, ELISA, FC | Mouse IgG |
TAB-437CT | Mouse Anti-SFRP5 Recombinant Antibody (TAB-437CT) | WB, ELISA, FC | Mouse IgG2b, κ |
TAB-438CT | Mouse Anti-SFRP5 Recombinant Antibody (TAB-438CT) | WB, ELISA, FC | Mouse IgG2b, κ |
TAB-439CT | Mouse Anti-SFRP5 Recombinant Antibody (TAB-439CT) | WB, ELISA, FC | Mouse IgG2a, κ |
TAB-436CT-F(E) | Mouse Anti-SFRP5 Recombinant Antibody; Fab Fragment (TAB-436CT-F(E)) | WB, ELISA, FC | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1954CQ | Recombinant Mouse Anti-SFRP5 Antibody (CBL640) | Neut | IgG2b |
There are currently no Customer reviews or questions for HPAB-0008-DJB. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.